Compare
Up to four compounds, side by side.
Useful for choosing between similar peptides or planning a stack.
Add a peptide
| Attribute | GLP-1 / GIP / Glucagon Triple Agonist Retatrutide |
|---|---|
| Summary | Investigational triple-agonist with the largest weight-loss numbers in early trials. |
| Mechanism | Triple-agonist targeting GLP-1, GIP, and glucagon receptors for additive metabolic effect. |
| Top outcomes |
|
| Evidence | emerging |
| Half-life | ~6 days (estimated) |
| Administration | subq |
| Legal status | research only |
| Safety | Side-effect profile similar to other GLP-class drugs; long-term data pending. |